Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Anokion allies with Astellas and forms Kanyos to develop compounds

Executive Summary

Astellas Pharma Inc. and Anokion SA are teaming up to develop compounds for Type I diabetes and celiac disease. Anokion created Kanyos Bio Inc. to develop the candidates and the spin-off concurrently raised $16mm from Astellas, individual investors, and Anokion's Series A backers Versant Ventures, Novo Ventures, and Novartis Venture Fund.
Deal Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes M&A Option
    • R+D and Marketing-Licensing

Related Companies